AUTHOR=Yang Qian , Ding Peng , Liu Yu-xiang , Zhang Kai-chen , Gao Pei-yang 

TITLE=Case Report: Severe Pneumocystis jirovecii pneumonia following zuberitamab treatment in autoimmune hemolytic anemia

JOURNAL=Frontiers in Immunology

VOLUME=Volume 16 - 2025

YEAR=2025

URL=https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1546571

DOI=10.3389/fimmu.2025.1546571

ISSN=1664-3224

ABSTRACT=The pathogenesis of autoimmune hemolytic anemia (AIHA) remains incompletely understood, typically associated with immune dysfunction and the production of autoantibodies. Zuberitamab, a novel anti-CD20 monoclonal antibody, represents an important therapeutic strategy for managing autoimmune diseases. Here, we present the first case of a patient diagnosed with AIHA who developed severe immunosuppression, lymphopenia, and B-cell depletion following zuberitamab treatment, ultimately resulting in severe Pneumocystis jirovecii pneumonia(PJP). This case highlights the complexities of B-cell-targeted immunotherapy and underscores the necessity of close monitoring of immune status in patients receiving zuberitamab or other targeted immunotherapies to mitigate the risk of severe immune-related adverse events.